[go: up one dir, main page]

AR035497A1 - Compuestos no-imidazol, composicion farmaceutica que los comprenden y el uso de los mismos para la preparacion de medicamentos - Google Patents

Compuestos no-imidazol, composicion farmaceutica que los comprenden y el uso de los mismos para la preparacion de medicamentos

Info

Publication number
AR035497A1
AR035497A1 ARP010104831A ARP010104831A AR035497A1 AR 035497 A1 AR035497 A1 AR 035497A1 AR P010104831 A ARP010104831 A AR P010104831A AR P010104831 A ARP010104831 A AR P010104831A AR 035497 A1 AR035497 A1 AR 035497A1
Authority
AR
Argentina
Prior art keywords
alkyl
aryl
formula
halogen
alkylaryl
Prior art date
Application number
ARP010104831A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR035497A1 publication Critical patent/AR035497A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)

Abstract

Un compuesto que tiene la fórmula (1) o una sal o solvato farmacéuticamente aceptable de la misma, en la cual: (1) R1 está seleccionado de: arilo, heteroarilo, heterocicloalquilo, alquilo, cicloalquilo, o alquilarilo, donde dichos grupos R1 están opcionalmente sustituidos con 1 a 4 sustituyentes independientemente seleccionados de: halógeno, hidroxilo, alcoxi inferior, -CF3, CF3O, -NR4R5, fenilo, -NO2, -CO2R4, -CON(R4)2 donde cada R4 es igual o diferente, -S(O)mN(R20)2 donde cada R20 es igual o diferente H o un grupo alquilo preferiblemente alquilo C1-4, más preferiblemente alquilo C1-2 y más preferiblemente metilo, -CN, o alquilo, o (2) R1 y X tomados conjuntamente forman un grupo seleccionado de fórmula (2) o (3); (3) X está seleccionado de: =C(O), =C(NOR3), =C(NNR4R5), fórmula (4) o (5), (4) M1 es carbono, (5)M2 está seleccionado de C o N, (6) M3 y M4 están independientemente seleccionados de C o N, (7) Y está seleccionado de: -CH2-, =C(O), =C(NOR20)(donde R20 es tal como se ha definido anteriormente), o =C(S), (8) Z es un grupo alquilo C1-6, (9) R2 es un anillo heteroarilo de 5 o 6 miembros, comprendiendo dicho anillo heteroarilo de 6 miembros 1 o 2 átomos de nitrógeno, siendo los átomos remanentes carbono, y conteniendo dicho anillo heteroarilo de 5 miembros 1 o 2 heteroátomos seleccionados de: nitrógeno, oxígeno o azufre, siendo el resto de los átomos del anillo carbono; estando opcionalmente dicho anillo heteroarilo de 5 o 6 miembros opcionalmente sustituidos con 1 a 3 sustituyentes independientemente seleccionados de: halógeno, hidroxilo, alquilo inferior, alcoxi inferior, -CF3, CF3O-, -NR4R5, fenilo, -NO2, -CO2R4, -CON(R4)2, donde cada R4 es igual o diferente, -CH2NR4R5, -(N)C(NR4R5)2, -CN; (10) R3 está seleccionados de hidrógeno, alquilo C1-6, arilo, heteroarilo, heterocicloalquilo, arilalquilo, -(CH2)e-C(O)N(R4)2 donde cada R4 es igual o diferente, -(CH2)e-C(O)OR4, -(CH2)e-C(O)R30 donde R30 es un grupo heterocicloalquilo, tal como por ejemplo, morfolinilo, piperidinilo, piperazinilo o pirrolidinilo, que incluye fórmula (6), -CF3, o -CH2CF3, donde dicho arilo, heteroarilo, heterocicloalquilo y la porción arilo de dicho arilalquilo, están opcionalmente sustituidos con 1 a 3 sustituyentes seleccionados de: halógeno, -OH, -OCF3, -CF3, -CN, -N(R45)2, -CO2R45, o -C(O)N(R45)2, donde cada R45 está independientemente seleccionado de: H, alquilo, alquilarilo o alquilarilo donde dicha porción arilo está sustituida con 1 a 3 sustituyentes independientemente seleccionados de -CF3, -OH, halógeno, alquilo, -NO2, o -CN; (11) R4 está seleccionado de: hidrógeno, alquilo C1-6, arilo, alquilarilo, estando dichos grupos arilo y alquilarilo opcionalmente sustituidos con 1 a 3 sustituyentes seleccionados de: halógeno, -CF3, -OCF3, -OH, -N(R45)2, -CO2R45, -C(O)N(R45)2, o -CN, donde R45 es tal como se ha definido anteriormente; (12) R5 está seleccionado de hidrógeno, alquilo C1-6, -C(O)R4, -C(O)2R4, o -C(O)N(R4)2, donde cada R4 está independientemente seleccionado, y R4 es tal como se ha definido anteriormente; (13) o R4 y R5 tomados conjuntamente con el átomo de nitrógeno al cual están unidos forman un anillo heterocicloalquilo de 5 o 6 miembros; (14) R6 está seleccionado de: alquilo, arilo, alquilarilo, halógeno, hidroxilo, alcoxi inferior, -CF3, CF3O-, -NR4R5, fenilo, -NO2, -CO2R4, -CON(R4)2, donde cada R4 es igual o diferente, o -CN; (15) R12 está seleccionado de: alquilo, hidroxilo, alcoxi o flúor; (16) R3 está seleccionado de: alquilo, hidroxilo, alcoxi o flúor; (17) a es 0 a 2; (18) b es 0 a 2; (19) c es 0 a 2; (20) e es 0 a 5; (21) m es 1 o 2; (22) n es 1, 2 o 3; y (23) p es 1, 2 o 3, con la condición de que cuando M3 y M4 son ambos nitrógeno, entonces p es 2 o 3. También se describen composiciones farmacéuticas que comprenden los compuestos de la fórmula (1). Se describen también composiciones farmacéuticas que comprende los compuestos de la fórmula (1) para tratar varias enfermedades o condiciones, tales como por ejemplo alergia, respuestas de las vías respiratorias inducidas por alergia, y congestión (congestión nasal) usando los compuestos de la fórmula (1) en combinación con un antagonista receptor H1. Asimismo se describen el uso de dichos compuestos para la manufactura de medicamentos métodos para tratar varias enfermedades o condiciones, tales como, por ejemplos, alergia, respuestas de las vías respiratorias inducidas por alergia, y congestión (por ejemplo, congestión nasal), usando los compuestos de la fórmula (1).
ARP010104831A 2000-10-17 2001-10-15 Compuestos no-imidazol, composicion farmaceutica que los comprenden y el uso de los mismos para la preparacion de medicamentos AR035497A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24090100P 2000-10-17 2000-10-17

Publications (1)

Publication Number Publication Date
AR035497A1 true AR035497A1 (es) 2004-06-02

Family

ID=22908389

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010104831A AR035497A1 (es) 2000-10-17 2001-10-15 Compuestos no-imidazol, composicion farmaceutica que los comprenden y el uso de los mismos para la preparacion de medicamentos

Country Status (30)

Country Link
US (3) US6720328B2 (es)
EP (2) EP1326858B1 (es)
JP (2) JP4093859B2 (es)
KR (1) KR100567266B1 (es)
CN (2) CN1803795B (es)
AR (1) AR035497A1 (es)
AT (2) ATE420863T1 (es)
AU (2) AU2002215355B2 (es)
BR (1) BR0114754A (es)
CA (1) CA2424664C (es)
CY (2) CY1105227T1 (es)
DE (2) DE60115937T2 (es)
DK (2) DK1326858T3 (es)
EC (1) ECSP034559A (es)
ES (2) ES2320008T3 (es)
HK (1) HK1052935B (es)
HU (1) HUP0303835A3 (es)
IL (1) IL155031A0 (es)
MX (1) MXPA03003529A (es)
NO (1) NO325997B1 (es)
NZ (1) NZ524857A (es)
PE (1) PE20020507A1 (es)
PL (1) PL361978A1 (es)
PT (1) PT1571145E (es)
RU (2) RU2301231C2 (es)
SI (1) SI1326858T1 (es)
SK (1) SK4672003A3 (es)
TW (2) TWI258474B (es)
WO (1) WO2002032893A2 (es)
ZA (1) ZA200302521B (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020507A1 (es) * 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
GB2373186A (en) * 2001-02-23 2002-09-18 Astrazeneca Ab Pharmaceutical combinations of a CCR3 antagonist and a compound which is usefulreatment of asthma, allergic disease or inflammation
WO2002072570A2 (en) * 2001-03-13 2002-09-19 Schering Corporation Non-imidazole compounds as histamine h3 antagonists
AR036881A1 (es) * 2001-10-15 2004-10-13 Schering Corp Un proceso para la preparacion de 4-(piperidil)(2-piridil)metanona-(e)-o-metiloxima y sales
JP4384918B2 (ja) * 2002-04-18 2009-12-16 シェーリング コーポレイション ヒスタミンｈ３アンタゴニストとして有用な（１−４−ピペリジニル）ベンズイミダゾール誘導体
NZ535764A (en) 2002-04-18 2007-10-26 Schering Corp 1-(4-piperidinyl) benzimidazolones as histamine H3 antagonists
US7105505B2 (en) 2002-04-18 2006-09-12 Schering Corporation Benzimidazole derivatives useful as histamine H3 antagonists
AR039718A1 (es) * 2002-06-24 2005-03-09 Schering Corp Derivados de indol utiles como antagonistas de la histamina h3
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US8673924B2 (en) 2002-09-04 2014-03-18 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
PL224879B1 (pl) 2002-09-04 2017-02-28 Pharmacopeia Drug Discovery Inc Pirazolo [1,5-a] pirymidynowy związek, jego zastosowanie do wytwarzania leku oraz zawierająca go farmaceutyczna kompozycja
NZ540612A (en) 2003-01-14 2008-02-29 Arena Pharm Inc 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
WO2004066960A2 (en) * 2003-01-28 2004-08-12 Schering Corporation Combination of h1, h3 and h4 receptor antagonists for treatment of allergic and non-allergic pulmonary inflammation, congestion and allergic rhinitis
CA2523431A1 (en) 2003-04-23 2004-11-25 Glaxo Group Limited Piperazine derivatives and their use for the treatment of neurological and psychiatric diseases
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
WO2005014571A1 (en) * 2003-07-18 2005-02-17 Glaxo Group Limited Substituted piperidines as histamine h3 receptor ligands
US20060030550A1 (en) * 2004-08-04 2006-02-09 Lithgow Theodore L Pharmaceutical formulations
GB0420831D0 (en) * 2004-09-17 2004-10-20 Glaxo Group Ltd Novel compounds
ATE450526T1 (de) * 2005-06-20 2009-12-15 Schering Corp Als antagonisten von histamin h3 geeignete piperidinderivate
ES2337728T3 (es) * 2005-06-20 2010-04-28 Schering Corporation Piperidinas sustituidas unidas a carbono y sus derivados utiles como antagonistas de histamina h3.
US7332604B2 (en) * 2005-09-20 2008-02-19 Schering Corporation 1-[[1-[(2-Amino-6-methyl-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]piperidine
PE20071162A1 (es) * 2005-12-21 2007-11-30 Schering Corp Combinacion de un antagonista/agonista inverso de h3 y un supresor del apetito
MX2008008337A (es) * 2005-12-21 2008-09-03 Schering Corp Fenoxipiperidinas y sus analogos utiles como antagonistas de histamina h3.
JP2009521451A (ja) 2005-12-21 2009-06-04 シェーリング コーポレイション ヒスタミンｈ３アンタゴニストとして有用な置換アニリン誘導体
EP1962835A2 (en) * 2005-12-21 2008-09-03 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or h3 receptor antagonist/inverse agonist
BRPI0706623A2 (pt) 2006-01-18 2011-04-12 Schering Corp moduladores de receptor canabinóide
JP2010520199A (ja) * 2007-03-02 2010-06-10 シェーリング コーポレイション ピペリジン誘導体およびその使用方法
KR20100051625A (ko) * 2007-06-28 2010-05-17 인터벳 인터내셔널 비.브이. Ｃｂ1 길항제로서의 치환된 피페라진
BRPI0818626A2 (pt) * 2007-10-17 2015-09-29 Sanofi Aventis n-fenil-bipirrolidina carboxamidas substituída e uso terapêutico da mesma
WO2009052062A1 (en) * 2007-10-17 2009-04-23 Sanofi-Aventis Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
AU2008312641A1 (en) * 2007-10-17 2009-04-23 Sanofi-Aventis Substituted N-phenyl-bipyrrolidine ureas and therapeutic use thereof
CA2702834C (en) * 2007-10-17 2013-01-15 Sanofi-Aventis Substituted n-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof
US8383657B2 (en) * 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
US20090221648A1 (en) * 2007-12-21 2009-09-03 Abbott Laboratories Compositions for treatment of cognitive disorders
CA2739668C (en) 2008-01-04 2016-10-11 Schabar Research Associates Llc The use of analgesic potentiating compounds to potentiate the analgesic properties of an analgesic compound
WO2010027567A2 (en) 2008-07-23 2010-03-11 Schering Corporation Tricyclic spirocycle derivatives and methods of use thereof
JP2012505899A (ja) 2008-10-16 2012-03-08 シェーリング コーポレイション アジン誘導体およびそれの使用方法
US20110245267A1 (en) 2008-12-19 2011-10-06 Schering Plough Corporation Piperidine and piperazine derivatives and methods of use thereof
WO2010071819A1 (en) 2008-12-19 2010-06-24 Schering Corporation Bicyclic heterocyclic derivatives and methods of use thereof
TWI495637B (zh) * 2009-04-22 2015-08-11 Janssen Pharmaceutica Nv 用作單醯基甘油脂肪酶抑制劑之雜芳族及芳族六氫吡基吖丁啶基醯胺（一）
US20120171126A1 (en) 2009-06-16 2012-07-05 Purakkattle Biju J NOVEL [3,2-c] HETEROARYL STEROIDS AS GLUCOCORTICOID RECEPTOR AGONISTS COMPOSITIONS AND USES THEREOF
PL2473049T3 (pl) 2009-09-04 2019-07-31 Biogen Ma Inc. Inhibitory kinazy tyrozynowej brutona
PH12012501385A1 (en) * 2010-01-22 2014-10-22 Taiho Pharmaceutical Co Ltd Piperazine compound having a pgds inhibitory effect
CN103221410B (zh) 2010-09-22 2017-09-15 艾尼纳制药公司 Gpr119受体调节剂和对与其相关的障碍的治疗
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
CN105315267B (zh) * 2014-07-30 2019-06-04 江苏恩华药业股份有限公司 一种酰胺类衍生物及其应用
EP4445956A3 (en) 2015-01-06 2024-12-04 Arena Pharmaceuticals, Inc. Compound for use in treating conditions related to the s1p1 receptor
PL3310760T3 (pl) 2015-06-22 2023-03-06 Arena Pharmaceuticals, Inc. Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1
WO2018017153A1 (en) 2016-07-21 2018-01-25 Biogen Ma Inc. Succinate forms and compositions of bruton's tyrosine kinase inhibitors
MA47504A (fr) 2017-02-16 2019-12-25 Arena Pharm Inc Composés et méthodes de traitement de l'angiocholite biliaire primitive
ES2987794T3 (es) 2018-06-06 2024-11-18 Arena Pharm Inc Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1
CN110105263A (zh) * 2019-05-13 2019-08-09 常州大学 一种阿米卡星中间体的合成方法
KR20230051164A (ko) 2020-07-15 2023-04-17 샤바르 리서치 어소시에이츠 엘엘씨 급성 통증의 치료 및 속쓰림의 중증도 및/또는 위험의 감소를 위한 이부프로펜 및 파모티딘으로 구성된 단위 경구 투여 조성물
US11324727B2 (en) 2020-07-15 2022-05-10 Schabar Research Associates, Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn
US12514846B2 (en) 2020-07-15 2026-01-06 Schabar Research Associates Llc Unit oral dose compositions composed of ibuprofen or a pharmaceutically acceptable salt thereof and famotidine or a pharmaceutically acceptable salt thereof for the treatment of acute pain and the reduction of the severity and/or risk of heartburn and/or upset stomach

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6062590A (en) 1989-07-07 1991-02-06 Schering Corporation Pharmaceutically active compounds
US5807872A (en) 1992-12-16 1998-09-15 Schering Corporation Imidazoylalkyl substituted with a six membered nitrogen containing heterocyclic ring
US5633250A (en) 1991-12-18 1997-05-27 Schering Corporation Imidazoylalkyl substituted with a six or seven membered heterocyclic ring containing two nitrogen atoms
SG44510A1 (en) 1991-12-18 1997-12-19 Schering Corp Imidazolyl or imidazoylalkyl substituted with a four or five membered nitrogen containing heterocyclic ring
HUT74386A (en) 1993-11-15 1996-12-30 Schering Corp Phenyl-alkyl imidazoles as h3-receptor antagonists and pharmaceutical compositions containing them
WO1997019074A1 (en) * 1995-11-17 1997-05-29 Hoechst Marion Roussel, Inc. Substituted 4-(1h-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
JP3638289B2 (ja) 1996-08-16 2005-04-13 シェーリング コーポレイション ヒスタミンレセプターアンタゴニストの組み合わせを用いる上気道アレルギー性応答の処置
US5869479A (en) 1997-08-14 1999-02-09 Schering Corporation Treatment of upper airway allergic responses
CA2308586A1 (en) 1997-11-07 1999-05-20 Schering Corporation H3 receptor ligands of the phenyl-alkyl-imidazoles type
US6034251A (en) 1997-11-07 2000-03-07 Schering Corporation Phenyl-alkyl-imidazoles
US5990147A (en) 1997-11-07 1999-11-23 Schering Corporation H3 receptor ligands of the phenyl-alkyl-imidazoles type
RU2135454C1 (ru) * 1998-03-30 1999-08-27 Сосна Михаил Хаймович Переработка природного газа с получением метанола
WO2000021512A2 (en) * 1998-10-09 2000-04-20 Schering Corporation Composition and method for treating allergic diseases
US6100279A (en) 1998-11-05 2000-08-08 Schering Corporation Imidazoylalkyl substituted with a five, six or seven membered heterocyclic ring containing one nitrogen atom
PE20020507A1 (es) * 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
WO2002072570A2 (en) 2001-03-13 2002-09-19 Schering Corporation Non-imidazole compounds as histamine h3 antagonists
NZ535764A (en) * 2002-04-18 2007-10-26 Schering Corp 1-(4-piperidinyl) benzimidazolones as histamine H3 antagonists
US7105505B2 (en) * 2002-04-18 2006-09-12 Schering Corporation Benzimidazole derivatives useful as histamine H3 antagonists
AR039718A1 (es) * 2002-06-24 2005-03-09 Schering Corp Derivados de indol utiles como antagonistas de la histamina h3
US20040198743A1 (en) * 2003-01-31 2004-10-07 Schering Corporation Methods for treating allergic skin and allergic ocular conditions using combinations of histamine receptor antagonists

Also Published As

Publication number Publication date
NZ524857A (en) 2004-12-24
CY1110262T1 (el) 2015-01-14
CN1803795B (zh) 2010-05-12
US20040097513A1 (en) 2004-05-20
JP2007145866A (ja) 2007-06-14
DE60115937T2 (de) 2006-06-29
HUP0303835A2 (hu) 2004-03-01
ATE420863T1 (de) 2009-01-15
EP1326858A2 (en) 2003-07-16
PL361978A1 (en) 2004-10-18
WO2002032893A2 (en) 2002-04-25
US20080119487A1 (en) 2008-05-22
HK1052935B (en) 2006-05-19
DK1571145T3 (da) 2009-05-04
HK1052935A1 (en) 2003-10-03
JP2004511553A (ja) 2004-04-15
RU2007104096A (ru) 2008-08-10
DK1326858T3 (da) 2006-05-08
JP4093859B2 (ja) 2008-06-04
PE20020507A1 (es) 2002-06-25
US7300941B2 (en) 2007-11-27
CN1469873A (zh) 2004-01-21
ATE312833T1 (de) 2005-12-15
KR100567266B1 (ko) 2006-04-03
NO325997B1 (no) 2008-09-01
ZA200302521B (en) 2004-06-30
TW200510368A (en) 2005-03-16
PT1571145E (pt) 2009-04-07
HK1081182A1 (en) 2006-05-12
AU2002215355B2 (en) 2006-09-14
CN1803795A (zh) 2006-07-19
KR20030036931A (ko) 2003-05-09
NO20031744D0 (no) 2003-04-15
CA2424664C (en) 2008-12-23
EP1571145B1 (en) 2009-01-14
EP1571145A1 (en) 2005-09-07
HUP0303835A3 (en) 2009-08-28
CA2424664A1 (en) 2002-04-25
MXPA03003529A (es) 2003-08-07
BR0114754A (pt) 2003-07-01
ECSP034559A (es) 2003-06-25
DE60115937D1 (de) 2006-01-19
DE60137461D1 (de) 2009-03-05
NO20031744L (no) 2003-06-14
CY1105227T1 (el) 2010-03-03
IL155031A0 (en) 2003-10-31
WO2002032893A3 (en) 2002-08-22
ES2250500T3 (es) 2006-04-16
CN1243751C (zh) 2006-03-01
SI1326858T1 (sl) 2006-04-30
TWI258474B (en) 2006-07-21
TWI292399B (en) 2008-01-11
US20030045519A1 (en) 2003-03-06
SK4672003A3 (en) 2003-11-04
EP1326858B1 (en) 2005-12-14
US6720328B2 (en) 2004-04-13
ES2320008T3 (es) 2009-05-18
AU1535502A (en) 2002-04-29
RU2301231C2 (ru) 2007-06-20

Similar Documents

Publication Publication Date Title
AR035497A1 (es) Compuestos no-imidazol, composicion farmaceutica que los comprenden y el uso de los mismos para la preparacion de medicamentos
AR035349A1 (es) Compuestos de pirimidinona, composiciones farmaceuticas que los comprenden, uso de tales compuestos en la fabricacion de medicamentos y proceso para la preparacion de dichos compuestos
AR023152A1 (es) Compuesto tienopirimidina, procedimiento para producirlo, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar dichacomposicion
ECSP034475A (es) Derivados de 4-fenil-piridin como antagonistas del receptor de neuroquinina-1
PE20030703A1 (es) Inhibidores de la 17b-hidroxiesteroide deshidrogenasa tipo 3
AR035068A1 (es) Compuestos de pirimidinona, composiciones farmaceuticas que los comprenden, uso de tales compuestos en la fabricacion de medicamentos y proceso para la preparacion de dichos compuestos
PT1289955E (pt) Piperidinas para utilizacao como antagonistas dos receptores da orexina
AR035369A1 (es) Derivados de tetrahidrobenzazepina composiciones farmaceuticas que los comprenden, el uso de dichos derivados en la fabricacion de medicamentos, e intermediarios utiles en la preparacion de dichos compuestos
AR040405A1 (es) Derivados de bencimidazol utiles como antagonistas de histamina h3
AR037489A1 (es) Quinolinas sustituidas y proceso para su preparacion
AR035440A1 (es) Compuestos antagonistas del receptor h3, el uso de los mismos solos o en combinacion para la manufactura de medicamentos y composiciones farmaceuticas
AR110153A1 (es) ÁCIDOS PROPIÓNICOS 3-SUSTITUIDOS COMO INHIBIDORES DE LA INTEGRINA aV
AR076860A1 (es) Derivados de 7-aril- 1,2,4-triazolo[4,3-a]piridina moduladores alostericos positivos de receptores mglur2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos neurologicos y siquiatricos.
ECSP034431A (es) N-oxidos como profarmacos antagonistas del receptor nk1 de derivados de 4-fenil-piridina
CO5640041A2 (es) Un inhibidor de pde4 y un agente anticolinergico en combinacion para tratar enfermedades obstructivas de vias respiratorias
AR063804A1 (es) Compuestos de azoniabiciclo[2.2.2]octano
PE20030761A1 (es) Derivados del 7-amino-benzotiazol
AR056613A1 (es) Compuestos derivados de lapachona, su preparacion y metodos de uso de los mismos para el tratamiento o prevencion de trastornos proliferativos celulares y composiciones farmaceuticas que los contienen
JO1645B1 (en) Pyridazine compounds are antibacterial viruses
AR034174A1 (es) Compuestos de benzoxazinona, procedimiento para su preparacion, composiciones farmaceuticas que lo comprenden, procedimiento para la preparacion de tales composiciones, y el uso de dichos compuestos o composiciones en la fabricacion de medicamentos
GB1046506A (en) Guanidine compounds and process for their manufacture
AR007108A1 (es) Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes.
AR034585A1 (es) Nuevos compuestos de dihidropirimidina ciano substituidos y su uso para tratar padecimientos
PE20030719A1 (es) Derivados de 8-[bis(2-halofenil)metil]-3-heteroaril-8-azabiciclo[3.2.1] octan-3-ol como agonistas del receptor de nociceptina orl-1
NO156526C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive 1-fenyl-2-aminocarbonylindol-forbindelser.

Legal Events

Date Code Title Description
FC Refusal
FB Suspension of granting procedure